TB-500 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What TB-500 Does & How It Works

What It Does: Functional Outcomes

• Accelerates healing of soft tissue injuries (tendons, ligaments, muscle, and skin) by mobilizing repair cells throughout the body
• Reduces systemic inflammation, particularly chronic low-grade inflammation that slows recovery
• Stimulates the growth of new blood vessels into oxygen-deprived or damaged tissue, improving nutrient and repair-cell delivery
• Supports cardiac tissue repair following ischemic injury in preclinical models
• Promotes myelin-producing cell generation and reduces neuroinflammation in neurological injury models
• Extends the reach of repair beyond the injection site: because it distributes systemically, it addresses injuries throughout the body rather than only near where it is administered

How It Works: Mechanism of Action

Actin Sequestration and Cytoskeletal Regulation (Evidence: In vitro: Dominguez & Holmes, 2011, Annual Review of Biophysics)

TB-500 binds to G-actin monomers (the globular, unpolymerized form of actin) and regulates whether they assemble into filamentous structures. By controlling how and when actin assembles, TB-500 directly influences how cells change shape and move toward injury sites.

VEGF Upregulation and Angiogenesis (Evidence: Animal / In vitro: Goldstein et al., 2005, Trends in Molecular Medicine)

TB-500 upregulates VEGF (vascular endothelial growth factor, the primary signaling protein that tells the body to build new blood vessels) through the HIF-1 alpha (a protein that activates genes in low-oxygen conditions) pathway. It also engages Notch signaling (a cell communication system that governs cell fate decisions) in developing blood vessels. The result is both a signal to build new vessels and the physical cell movement needed to construct them.

NF-kB Suppression and Anti-Inflammatory Signaling (Evidence: Animal / In vitro)

TB-500 suppresses activation of NF-kB (a master transcription factor, meaning a protein that switches dozens of inflammatory genes on simultaneously), reducing downstream pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6. It also shifts macrophage polarization from the M1 phenotype (pro-inflammatory, tissue-damaging) to the M2 phenotype (repair-promoting). The net effect is selective suppression of chronic, excessive inflammation without eliminating the acute healing response.

Akt/PI3K Cell Survival and Anti-Apoptotic Mechanisms (Evidence: Animal / In vitro)

TB-500 activates the Akt/PI3K pathway (a central cell survival and proliferation signaling cascade) and modulates BCL-2 expression (an anti-apoptotic protein that promotes cell survival) along with caspase inhibition (caspases are enzymes that execute programmed cell death) to reduce apoptotic (programmed cell death) activity in damaged tissue environments. This helps repair cells survive long enough to do their work in the hostile biochemical environment of an injury site.

TB-500 Molecular Profile

Structure reference: View TB-500 (PubChem CID 16132341) on PubChem - Publishing team: retrieve 2D structure image from this link.

A note on the molecular weight figure: The molecular weight of 4,963.4 g/mol reflects the full TB-500 compound including the acetylated heptapeptide structure. TB-500 is not the full thymosin beta-4 protein; it is the 7-amino acid active actin-binding domain fragment, acetylated at the N-terminus. This smaller size relative to full-length proteins is a key factor in TB-500's systemic distribution and tissue penetration properties.

TB-500 Uses & Benefits

Soft Tissue Injury Recovery

TB-500 is most commonly researched and used in practice for soft tissue injuries: tendons, ligaments, muscle tears, and skin wounds. The primary mechanism is actin-regulated cell migration; by enhancing the motility of fibroblasts (connective tissue repair cells), keratinocytes (skin repair cells), and endothelial cells (cells that line blood vessels), TB-500 accelerates the physical process of repair cell recruitment to injury sites throughout the body. The VEGF upregulation and angiogenic mechanisms are particularly relevant for tendon injuries, which have limited native blood supply and heal slowly in part because of restricted nutrient delivery. (Evidence: Moderate: animal models)

Systemic Anti-Inflammation

Beyond localized injury contexts, TB-500 is used for its systemic anti-inflammatory properties, particularly in contexts of chronic low-grade inflammation that spans multiple tissue systems. NF-kB suppression, cytokine reduction, and macrophage M2 polarization all contribute to a reduction in inflammatory load without the immunosuppressive effects associated with corticosteroids. Community protocol data shows use in autoimmune-adjacent contexts and general recovery optimization, though the evidence base for these applications is weaker than the injury-specific data. (Evidence: Moderate for mechanism: animal / in vitro; Preliminary for systemic anti-inflammatory application in humans)

Cardiac Repair Support

Cardiac applications represent one of the more scientifically developed areas for the parent TB4 compound, with Phase 2 human clinical trials conducted in acute myocardial infarction and congenital heart surgery contexts. Animal models show reduced infarct size, improved cardiac contractility, and promoted neovascularization in damaged cardiac tissue. A 2021 review identified TB4's role in reactivating embryonic-like epicardial repair programs in mouse hearts, a potentially novel mechanism for engaging dormant developmental repair pathways in adult cardiac tissue. Application of these findings to TB-500 specifically carries the standard extrapolation caveat. (Evidence: Moderate for TB4: Phase 2 human trials with incomplete published results; Preliminary for TB-500 specifically)

Neurological Recovery

Neurological applications draw from TB4 animal research demonstrating oligodendrogenesis stimulation (production of myelin-forming cells that insulate nerve fibers), axonal remodeling, and neuroinflammation reduction in demyelination and stroke models. The neuroprotective profile aligns with TB-500's general anti-inflammatory and cell survival mechanisms. TNF-alpha reduction, NF-kB suppression, Akt/PI3K activation, and anti-apoptotic effects all have relevance in neurological injury contexts. No dedicated TB-500 neurological studies have been published; all neurological data is extrapolated from TB4 research. (Evidence: Preliminary for TB-500 specifically: animal data for TB4)

Recovery Optimization and Performance

In community and practitioner protocol documentation, TB-500 is frequently used for broader recovery optimization: reducing systemic recovery time between training cycles, managing accumulated soft tissue load in active individuals, and addressing multiple minor injuries simultaneously through the systemic distribution mechanism. The rationale is that TB-500's whole-body reach allows it to address recovery broadly rather than requiring targeted administration at each individual injury site. This application is primarily documented through community protocol data rather than published research. (Evidence: Anecdotal / user-reported: no published research for this specific application)

Where This TB-500 Guide Comes From

TB-500 Results & Timelines

Soft Tissue Healing and Injury Recovery

• Week 1-2: Effects at this stage are often subtle. Some users report mild reduction in localized stiffness or an early sense of reduced discomfort at injury sites, but significant structural repair takes time and early reports are inconsistent.
• Week 3-4: More consistent signals begin appearing: improved range of motion, reduced pain with movement, and in some cases measurable reduction in swelling. This is roughly where the loading protocol starts showing compounding effect.
• Week 6-8: The window most commonly cited in tracked protocols for meaningful soft tissue improvement. Users report notable functional recovery for tendon and ligament injuries in this range. Some continue to see improvement through week 10-12.
• Beyond 8 weeks: During the maintenance phase, improvement typically continues but at a slower rate. Gains from the loading phase consolidate. Some users run a second loading cycle for severe injuries after a break.

Systemic Anti-Inflammation and General Recovery

• Week 1-2: Some users report early systemic anti-inflammatory signals: reduced general soreness, improved sleep quality, a broader sense of recovery improvement. These effects are variable and may reflect individual baseline inflammatory load.
• Week 3-6: More consistent reports of reduced systemic stiffness, improved recovery between training sessions, and reduced chronic pain in previously affected areas.

Cardiac and Neurological Applications

Timeline data for cardiac and neurological applications in human real-world use is sparse. These applications are primarily explored under medical supervision and are not commonly documented in community protocol logs in a way that produces reliable timeline patterns. Published animal research does not translate directly to human timeline expectations.

How to Administer TB-500

Subcutaneous Injection (SubQ)

SubQ injection (administered into the fat layer just beneath the skin) is the most commonly documented administration route for TB-500 in both research contexts and real-world protocols. Common injection sites include the abdomen, outer thigh, and lateral flank. Because TB-500 distributes systemically rather than locally, injection site proximity to an injury is not required, unlike some other peptides where local injection near a target tissue is preferred. SubQ is generally considered appropriate for the standard loading and maintenance dosing schedule.

Intramuscular Injection (IM)

IM injection (administered directly into muscle tissue) is used by some practitioners and documented in a portion of community protocols. IM administration may produce a slightly different absorption profile compared to SubQ, though specific bioavailability comparison data between IM and SubQ routes for TB-500 is not available in the published literature. IM may be preferred in some practitioner-supervised contexts for compounds with larger injection volumes. For most documented TB-500 protocols, SubQ is the more commonly reported route.

Nasal / Intranasal

Intranasal administration is not a documented route for TB-500. The compound is not formulated for intranasal use and no bioavailability data exists for this route. This section is included for completeness; nasal administration is not applicable for TB-500.

Oral

Oral administration of TB-500 is not considered effective for systemic use. As a peptide, TB-500 is subject to degradation by stomach acid and proteolytic enzymes in the digestive tract before it can be absorbed intact into the bloodstream. Unlike BPC-157, which has documented gastric acid stability and some evidence supporting oral activity, TB-500 does not share this characteristic. Oral formulations of TB-500 have no documented evidence of bioavailability in the published literature.

Topical

Topical administration is documented in preclinical wound healing research: some of the TB4 wound healing studies used topical application in animal models. However, topical TB-500 for systemic effect is not a standard or documented route for human use. For surface wound healing applications, topical use may be relevant based on preclinical data, but bioavailability data for systemic effect via topical route is not available.

TB-500 Dosage & Cycle Length

Overall dosing range: 2-7.66 mg per injection, range varies significantly by goal, protocol phase, and individual

The dosing picture for TB-500 is more complex than most peptides because the research involves multiple compounds (TB-500 and parent TB4), multiple dosing contexts (loading vs. maintenance), and a wide spread between the low-maintenance and high-acute-application ends of the spectrum. The ranges below reflect what appears across published animal research, Phase 1 and Phase 2 human TB4 safety trials, practitioner documentation, and real-world protocol data.

How the goal shifts where you land:

• Low end of range (2-2.5 mg per injection): commonly associated with maintenance protocols, injury prevention, and general systemic anti-inflammation, used by people who have completed a loading phase and are looking to sustain gains
• Mid range (2.5-5 mg per injection): the most commonly documented range for active injury recovery and standard loading protocols across tracked community use; this is where most people start
• High end of range (5-7.66 mg per injection): sometimes used in acute injury contexts or loading phases for more severe soft tissue injuries; the 7.66 mg figure appears in human TB4 Phase 1 safety trial data (evidence grade: Phase 1 human safety: TB4, extrapolated to TB-500)

Frequency: Loading phase: typically twice weekly. Maintenance phase: once weekly or once every two weeks, depending on goals and protocol structure.

Cycle length: Most documented protocols follow a loading and maintenance structure:

• Loading phase: 4-6 weeks, twice weekly dosing: the period of active tissue repair and angiogenesis stimulus
• Maintenance phase: 4-6 weeks following loading, once weekly or biweekly dosing: sustaining the effects established during loading
• Total cycle: 8-12 weeks is the most commonly reported full cycle length in tracked protocols
• Some users run shorter 4-6 week cycles for acute injuries, then discontinue

Loading protocols: A two-phase approach (higher-frequency dosing for the first 4-6 weeks followed by a step-down to lower-frequency maintenance) is the most commonly documented protocol structure in both practitioner guidance and community use. The rationale is to front-load the angiogenic and repair stimulus during active healing and then maintain systemic levels as tissue consolidates.

TB-500 Vial Sizes, Costs & Quality

Common vial sizes: 2 mg, 5 mg, 10 mg. Five-milligram vials are the most commonly available format; 10 mg vials are frequently used for loading protocols where per-dose amounts are higher.

Typical cost range: $60-$120 per vial for U.S.-manufactured research-grade TB-500 at current market pricing, varies by supplier, vial size, and purity level. Ten-milligram vials from domestic sources typically run $90-$140. TB-500 tends to be priced higher than shorter-chain peptides because synthesis of the full compound and its purification are more technically demanding.

Storage: lyophilized (dry powder):

• Temperature: Refrigerate at 2-8 degrees C for short-term storage; freeze at -20 degrees C for long-term storage
• Shelf life: 24 months or longer when properly stored at -20 degrees C; shorter at refrigerator temperatures
• Light sensitivity: Protect from light; store in opaque or light-blocking packaging

Storage: reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C after reconstitution
• Use window: Peptide quality degrades over time once in solution; most manufacturers recommend use within approximately 28-30 days for optimal potency

Normal appearance after reconstitution: TB-500 typically dissolves into a clear, colorless solution. Some slight opalescence (a faint milky quality) can be normal depending on concentration and solvent used. The solution should not appear visibly cloudy, chunky, or discolored beyond this mild characteristic.

Signs of degradation: Heavy cloudiness or visible particulates in a solution that was previously clear; discoloration such as yellow, brown, or pink tint; unusual odor; flocculation (visible clumping or floating material in the solution). Degraded peptide solution should not be used.

Quality Considerations

Peptide quality with TB-500 comes down to synthesis purity and correct structural modification. TB-500's N-terminal acetylation is a defining structural feature: it is what distinguishes the compound from a non-acetylated fragment and is directly tied to its stability and bioavailability. Verifying that a supplier is producing properly acetylated TB-500 rather than a cheaper, unmodified version requires third-party mass spectrometry verification. A lot of what circulates through lower-cost overseas channels is synthesized in facilities with no accountability structures, no independent testing requirements, and no chain of custody documentation, so the buyer has no reliable way to confirm they are getting what the label says. U.S.-manufactured peptides come with traceable manufacturing processes, documented synthesis standards, and certificates of analysis from independent testing labs. For a compound where the structural modification is central to the mechanism, that verification is not a minor convenience; it is the difference between using the right compound and using a cheaper approximation of it.

TB-500 Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: TB-500's pro-angiogenic and pro-proliferative mechanisms raise theoretical concern about supporting tumor vascularization and cancer cell survival. These concerns center on VEGF upregulation and cell survival signaling. No specific studies have examined TB-500 in cancer contexts, and there is no direct evidence of causation. Use in individuals with active cancer is not recommended on the basis of mechanism alone.
• History of hormone-sensitive malignancy: Insufficient data to confirm safety in individuals with hormone-sensitive cancers; caution is warranted given angiogenic and growth-promoting mechanisms.
• Recent cardiac events not under medical supervision: The same mechanisms that may support cardiac repair in controlled contexts could theoretically be disruptive in certain acute cardiac situations. Medical supervision is required for any cardiac-related use.

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with rapid or poorly controlled tissue growth conditions (e.g., active benign tumors, endometriosis): The pro-proliferative and pro-angiogenic mechanisms warrant caution; no specific contraindication data exists, but mechanism-based concern applies

Red Flags: Stop Use and Seek Medical Attention If:

• Chest pain, shortness of breath, or irregular heartbeat following dosing
• Severe allergic reaction symptoms: hives, throat tightening, difficulty breathing
• Sudden or significant blood pressure changes with associated symptoms
• Neurological symptoms: visual changes, one-sided weakness, sudden severe headache
• Persistent high fever or signs of injection site infection: spreading redness, warmth, or purulent discharge

Drug and Compound Interactions

No formal pharmacokinetic drug interaction studies have been conducted for TB-500 in humans. Theoretical interaction concerns exist based on mechanism: concurrent use with other pro-angiogenic compounds or growth factors may produce additive effects on vascularization that are difficult to predict without data. TB-500's anti-inflammatory mechanisms theoretically overlap with NSAIDs and corticosteroids, though whether this produces clinically meaningful interaction is unknown. In practice, TB-500 is most commonly documented in combination with BPC-157, where the actin pathway synergy is the primary rationale; no adverse interaction signals have been reported from this combination in available protocol data, though no controlled combination study exists.

TB-500 Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability Bioavailability data specific to TB-500 via SubQ or IM injection in humans is not available in the published literature. TB-500 is water soluble and compatible with standard physiological solutions, which supports absorption from injection sites. Specific bioavailability percentages have not been formally measured in humans; the available pharmacokinetic context comes primarily from TB4 protein studies and in vitro metabolism research.

Distribution TB-500's low molecular weight relative to full-length proteins is the key distribution characteristic. Unlike growth factors that bind to the extracellular matrix and remain localized near their release point, TB-500 can penetrate tissue over long distances and distribute systemically. No specific tissue concentration data exists from human studies. Animal models suggest uptake into cardiac, neural, and musculoskeletal tissue following systemic administration.

Half-Life TB-500 has an extended half-life compared to BPC-157, enabling the systemic distribution that is central to its mechanism. Specific half-life values have not been precisely measured in humans in published literature. The extended duration supports the once- or twice-weekly dosing patterns used in documented protocols, but the exact figure is estimated rather than directly measured from a human pharmacokinetic study.

Metabolism & Elimination In vitro metabolism research using human liver microsomes, S9 fractions (liver metabolic enzyme preparations), human plasma, and human serum identified the primary metabolic pathway as serial C-terminal cleavage: the sequential removal of amino acids from the C-terminus (tail end) of the peptide. The N-terminal acetylation protects the N-terminus from degradation, which is why C-terminal metabolites dominate. Elimination routes have not been fully characterized in human studies.

Data gap note: Half-life values for TB-500 in humans are not precisely established in the published literature. The extended duration relative to BPC-157 is referenced in research context but has not been directly measured via controlled human pharmacokinetic study. All pharmacokinetic data specific to human use should be interpreted with this limitation in mind.

Mechanistic Research

Actin Sequestration and Cytoskeletal Regulation (Evidence: In vitro: Dominguez & Holmes, 2011, Annual Review of Biophysics)

TB-500 binds to G-actin monomers, sequestering them from premature polymerization while also enabling organized assembly into F-actin filaments (the polymerized, functional form of actin) when the cellular context calls for it. Actin comprises up to 10% of total cellular protein, making this one of the highest-leverage regulatory mechanisms in cell biology. Downstream effects on keratinocyte migration, fibroblast activity, and endothelial cell behavior all trace back to this primary mechanism.

VEGF Upregulation and Angiogenesis (Evidence: Animal / In vitro: Goldstein et al., 2005, Trends in Molecular Medicine)

TB-500 upregulates VEGF expression through the HIF-1 alpha pathway and engages Notch signaling to regulate endothelial cell behavior during vessel formation. In preclinical models, this produces increased blood vessel density at wound and injury sites, improved vascularization of ischemic tissue, and enhanced capillary stabilization. The combined effect of VEGF upregulation and actin-mediated endothelial cell migration means TB-500 supports both the signaling stimulus for new vessel growth and the physical cell movement required to build those vessels.

NF-kB Suppression and Cytokine Modulation (Evidence: Animal / In vitro)

TB-500 suppresses NF-kB activation and reduces downstream pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6. Simultaneously, it shifts macrophage polarization from the M1 (pro-inflammatory) to the M2 (repair-promoting) phenotype, and the thymosin beta-4 sulfoxide specifically blocks neutrophil chemotaxis (the movement of neutrophils toward inflammatory signals). The net effect is a reduction in chronic, excessive inflammatory signaling without a blanket suppression of the acute healing response.

Akt/PI3K Cell Survival Signaling and Anti-Apoptotic Action (Evidence: Animal / In vitro)

TB-500 activates the Akt/PI3K pathway and modulates BCL-2 (an anti-apoptotic protein that promotes cell survival) expression and caspase inhibition to reduce programmed cell death in damaged tissue environments. Injured tissue is biochemically hostile: high oxidative stress and pro-apoptotic signals kill a significant proportion of the cells recruited for repair before they can finish the job. Enhancement of ERK1/2 (a kinase involved in cell repair and stress responses) and p38 MAPK (another repair-associated signaling kinase) pathways further supports sustained regenerative signaling throughout the tissue repair window. HGF (hepatocyte growth factor, a protein associated with tissue regeneration) upregulation adds an additional pro-regenerative signal to this cascade.

Metabolite Activity: The Prodrug Finding (Evidence: In vitro / Ex vivo: WADA-funded human tissue research)

In vitro metabolism research using human liver microsomes and plasma found that the TB-500 parent compound (Ac-LKKTETQ) did not demonstrate wound-healing activity directly in laboratory models. The metabolite Ac-LKKTE did demonstrate wound-healing activity, leading researchers to conclude that TB-500's wound-healing activity may be attributable to this metabolite rather than the parent compound. Serial C-terminal cleavage was identified as the primary metabolism pathway. Note: the full citation for this research is pending editorial confirmation; the finding is reported here as preliminary until the primary source document is verified.

Condition-Focused Research

Wound Healing and Soft Tissue Repair {#research-tissue}

Preclinical wound healing studies using thymosin beta-4 in rat and mouse models documented accelerated reepithelialization, enhanced collagen deposition at injury sites, and improved wound closure rates compared to untreated controls. Studies in diabetic and aged mouse models, populations where wound healing is inherently compromised, found particularly notable effects on keratinocyte migration, angiogenesis, and reduced inflammatory infiltration. The 2024 metabolite finding adds interpretive complexity: wound-healing activity observed in earlier preclinical studies may have been mediated by the Ac-LKKTE metabolite rather than the TB-500 parent compound directly. (Evidence: Animal: wound healing models; 2024 metabolite finding pending full citation confirmation)

Cardiovascular and Cardiac Repair {#research-cardiac}

Animal models of myocardial infarction demonstrated reduced infarct size, improved left ventricular contractile function, and promoted neovascularization within damaged cardiac tissue following TB4 administration. A 2021 review highlighted TB4's role in reactivating embryonic-like epicardial repair programs in mouse hearts. This mechanism may represent a novel approach to cardiac regeneration by re-engaging dormant developmental pathways. Phase 2 human clinical trials with the parent TB4 compound showed cardiac repair potential in acute myocardial infarction and congenital heart surgery contexts, though results from these trials have been incompletely reported in the published literature. (Evidence: Moderate: Animal models; Phase 2 human trials for TB4 with limited published results: Goldstein et al., 2005, Trends in Molecular Medicine)

Neurological Recovery {#research-neuro}

In autoimmune encephalomyelitis mouse models (a standard preclinical model for demyelinating conditions, where the protective coating around nerve fibers is lost), TB4 at 6 mg/kg across five doses reduced inflammation, stimulated oligodendrogenesis, and improved neurological function. Stroke models demonstrated optimal outcomes when dosing was administered 24 hours post-event, with enhanced axonal remodeling and reduced neuroinflammation. No dedicated neurological studies have been conducted for TB-500 specifically; all neurological data is extrapolated from TB4 research. (Evidence: Preliminary for TB-500 specifically: Animal models for TB4)

Ophthalmic Research {#research-ophthalmic}

A Phase 2 clinical trial of TB4 eye drops in dry eye disease (one of the few human trials in this compound class to report results) found a 35% reduction in patient-reported discomfort and a 59% reduction in corneal staining compared to placebo, with the compound categorized as safe and well-tolerated. Preclinical ophthalmic studies showed low apoptotic activity in toxin-exposed corneas and reduced dryness and inflammation. The trial used the full 43-amino acid TB4 protein, not the TB-500 fragment, so application to TB-500 requires the standard extrapolation caveat. (Evidence: Moderate: Phase 2 human trial for TB4; Preliminary for TB-500 specifically)

Musculoskeletal Recovery: BPC-157 Context {#research-musculoskeletal}

TB-500's musculoskeletal data is primarily inferred from wound healing and cell migration research. The companion compound BPC-157 has more direct musculoskeletal evidence. In rat Achilles tendon transection models, BPC-157 accelerated healing, improved biomechanical load-to-failure measurements, enhanced collagen organization, and demonstrated in vitro stimulation of tendocyte growth. (Evidence: Animal: Staresinic et al., 2006, Journal of Orthopaedic Research) This evidence base is directly relevant to the TB-500 + BPC-157 combination commonly used in musculoskeletal recovery protocols, where BPC-157's localized tendon and ligament data complements TB-500's systemic distribution and angiogenic mechanisms.

Safety & Tolerability Research

Phase 1 human safety trials using the parent TB4 compound (conducted in 84 healthy volunteers at single and multiple intravenous doses) reported no dose-limiting toxicities, no serious adverse events, and no drug accumulation at doses up to 7.66 mg. The compound was categorized as well-tolerated across the dose range tested. These findings provide the most direct human safety data relevant to TB-500, with the standard caveat that TB4 and TB-500 are not identical compounds. The one initiated Phase 1 trial specifically for TB-500 (begun in 2015) was cancelled by the sponsoring organization and results were never submitted or published: a significant gap in the TB-500-specific safety evidence base. Long-term human safety data for either compound is not available in the published literature.

Research Limitations

TB-500's evidence base has specific and important gaps that affect how the available data should be interpreted. The most significant: no completed, published human clinical trials exist for TB-500 specifically. The 2015 Phase 1 trial was cancelled without explanation and without publishing results. The vast majority of TB-500 evidence comes from animal models, with human data borrowed by extrapolation from Phase 1 and Phase 2 trials using the parent TB4 compound, which is a different molecule. The in vitro metabolite finding adds further complexity: if TB-500 functions as a prodrug and its wound-healing activity is mediated by the metabolite Ac-LKKTE, then existing preclinical studies that measured parent compound activity rather than metabolite activity may have been studying the wrong endpoint. There are also no published long-term safety studies for TB-500 in humans, no large-scale randomized controlled trials in any population, and no dose-response studies in humans establishing optimal dosing for any specific application.

Is TB-500 Legal? Regulatory & Sports Status

FDA status: TB-500 is not approved by the FDA for any human use indication. It is classified as a research compound in the United States: not approved for therapeutic use, compounding, or prescription. The FDA has not issued specific enforcement guidance against TB-500 by name as of July 2026, but it falls under the broader regulatory framework for unapproved new drugs and research compounds.

Research Use Only (RUO): In most countries, TB-500 is classified as a research compound not approved for human use. This classification means it may be legally manufactured and sold for in vitro or animal research purposes but is not authorized for human administration. Users bear legal responsibility for understanding the rules in their specific jurisdiction.

WADA / USADA status: TB-500 is banned under WADA's Prohibited List, classified under the S2 category covering peptide hormones, growth factors, related substances, and mimetics. This ban covers both in-competition and out-of-competition use. Research into TB-500's primary metabolites (Ac-LKKTE and Ac-LK) was conducted specifically to support urine screening method development for doping control laboratories. Athletes subject to WADA, USADA, or equivalent national anti-doping authority testing should treat TB-500 as detectable.

Country-specific notes: Regulatory classification varies by jurisdiction. In Australia, thymosin beta-4 and related compounds are classified under the Therapeutic Goods Administration framework and may carry different legal status than in the United States. Users in Australia, the United Kingdom, Canada, and the European Union should verify the current classification in their specific country before use, as regulations change and enforcement approaches differ.

Detection: WADA-affiliated researchers have developed urine screening methods for TB-500 based on its metabolites, specifically Ac-LK and Ac-LKKTE. The estimated detection window is approximately 72 hours from last dose, based on in vitro metabolite kinetics rather than a confirmed human urine excretion study.

TB-500 vs. Alternatives

Commonly Paired With: Synergistic Stacks

• TB-500 + BPC-157: The most documented pairing in the peptide research and community space. BPC-157 upregulates actin gene expression at the molecular level (upstream), while TB-500 organizes that actin into functional cellular structures for migration and repair (downstream), creating a complementary relationship at the molecular level. BPC-157 provides more localized, concentrated healing action via its shorter half-life; TB-500 provides systemic distribution for whole-body recovery. No controlled combination study exists: synergy is supported by mechanistic reasoning and community protocol data rather than a direct comparison trial.

• TB-500 + GHK-Cu: A less common pairing targeting skin and wound healing. GHK-Cu (copper peptide) has well-documented collagen-stimulating and anti-inflammatory properties with a particular focus on skin biology. Combined with TB-500's cell migration and angiogenesis mechanisms, the rationale is to support both the vascular and structural components of wound healing simultaneously. Documented primarily in community protocols and practitioner discussion; no published combination study exists.

• TB-500 + Ipamorelin / CJC-1295: Sometimes used together in recovery and anti-aging-oriented protocols. Growth hormone secretagogues like Ipamorelin and CJC-1295 drive systemic GH/IGF-1 signaling, which supports muscle, bone, and connective tissue broadly; TB-500 adds the specific actin-mediated repair mechanisms and angiogenic signaling. The combination targets complementary aspects of tissue repair: a systemic anabolic environment plus targeted repair mechanisms. No published combination data; documented in practitioner and community protocols.

Alternatives: When Another Peptide May Be Considered

BPC-157 When the injury is localized and the primary need is targeted, concentrated healing at a specific site rather than systemic effect, BPC-157 is often considered first or used alone. Its shorter half-life makes it more suitable for administration near an injury. Its gastric acid stability means it can be used orally for GI applications, something TB-500 cannot provide. It also has more direct musculoskeletal evidence in animal models. The trade-off is that BPC-157 does not provide TB-500's systemic reach or the same angiogenic breadth for distributed injuries.

Sermorelin / CJC-1295 / Ipamorelin For users whose primary goal is recovery optimization and performance rather than specific injury healing, growth hormone secretagogue peptides offer a different approach: stimulating the natural GH/IGF-1 axis for broad tissue anabolism and repair rather than targeted cytoskeletal and vascular mechanisms. These are generally better characterized in human dosing data and are sometimes available through licensed compounding pharmacies depending on jurisdiction. The mechanism and evidence base differ substantially from TB-500.

BPC-157 + TB-500 combination For many recovery-focused applications, the combination itself is the practical alternative to either compound used alone. The mechanistic complementarity and the substantial community documentation of the pairing make the combination a distinct option worth considering separately from either compound individually.

Comparison table:

Build Your TB-500 Protocol

FAQs

What is TB-500?

TB-500 is a synthetic heptapeptide fragment representing the actin-binding domain of thymosin beta-4, a naturally occurring protein found throughout human tissue. It is derived from a portion of the thymosin beta-4 sequence called Ac-LKKTETQ, which is the segment responsible for regulating actin dynamics in cells. TB-500 is used in research contexts for its studied effects on tissue repair, systemic anti-inflammation, angiogenesis, and cellular migration.

What does TB-500 do?

TB-500 regulates actin dynamics (the internal scaffolding that cells use to move, divide, and change shape), which in turn accelerates the migration of repair cells to injury sites throughout the body. In preclinical research, this translates to accelerated wound healing, reduced systemic inflammation, improved blood vessel formation in damaged tissue, and support for cardiac and neurological recovery. Because of its low molecular weight, it distributes systemically rather than acting only near the injection site.

How long does TB-500 take to work?

For soft tissue injuries, most users in documented protocols report initial changes (reduced stiffness, mild mobility improvement) within 2-4 weeks, with more significant improvement typically appearing in the 6-8 week window of a loading protocol. For systemic anti-inflammatory effects, some users report earlier signals in the 1-2 week range. Individual variation is significant and depends on injury severity, dose, frequency, and overall health.

What is the typical dose of TB-500?

The broad documented range for TB-500 is 2-7.66 mg per injection, with most protocols using 2-5 mg for standard loading phases administered twice weekly, followed by a lower-frequency maintenance phase. Human Phase 1 safety data for the parent TB4 compound extends to 7.66 mg without dose-limiting toxicity. Individual protocols vary substantially by goal and health status: exact dosing should be determined with consideration of your specific situation, which is what the MyPeptidePal protocol builder is designed to support.

Is TB-500 legal?

TB-500 is classified as a research compound not approved for human use in most jurisdictions, including the United States. It is not illegal to possess in many countries but is not authorized for therapeutic human use. For athletes, TB-500 is banned by WADA under the S2 category covering peptide hormones and growth factors, covering both in-competition and out-of-competition use. Users are responsible for understanding and complying with applicable laws and regulations in their specific location.

Can TB-500 be taken orally?

No: oral administration of TB-500 is not considered effective for systemic therapeutic use. As a peptide, TB-500 is degraded by stomach acid and digestive enzymes before it can be absorbed intact into the bloodstream. Unlike BPC-157, which has unusual gastric acid stability and some evidence supporting oral bioavailability, TB-500 does not share this characteristic. Documented administration routes are subcutaneous and intramuscular injection.

What is the difference between TB-500 and thymosin beta-4 (TB4)?

TB-500 is a synthetic fragment representing just the actin-binding domain of the larger thymosin beta-4 (TB4) protein, specifically the Ac-LKKTETQ heptapeptide segment. The full TB4 protein is 43-44 amino acids; TB-500's active motif is 7 amino acids. Most human clinical trial data in this research area used full-length TB4, not TB-500 specifically. Extrapolating TB4 human trial results to TB-500 is a reasonable inference based on the shared active domain, but it is an assumption rather than directly validated evidence.

Do TB-500 and BPC-157 work better together than separately?

The mechanistic rationale for combining them is sound: BPC-157 upregulates actin gene expression while TB-500 organizes that actin into functional cellular structures, creating a complementary upstream-downstream relationship at the molecular level. BPC-157 provides localized healing action while TB-500 distributes systemically, so together they address both local and systemic recovery. Community protocol data broadly supports the combination for recovery applications. No controlled combination study exists: the synergy evidence is mechanistic and observational rather than from a direct comparison trial.

Does TB-500 need to be refrigerated?

Lyophilized (dry powder) TB-500 should be refrigerated at 2-8 degrees C for short-term storage, or frozen at -20 degrees C for longer-term storage. Once in solution, it must be kept refrigerated at 2-8 degrees C and used within approximately 28-30 days for optimal potency. TB-500 should be protected from light in both dry and reconstituted form. Properly stored lyophilized TB-500 has an approximate shelf life of 24 months or longer when kept frozen.

Is TB-500 the same as PT-141 or BPC-157?

No: these are different compounds with different structures and mechanisms. TB-500 is a thymosin beta-4 fragment targeting actin regulation and tissue repair. BPC-157 is a 15-amino acid peptide derived from human gastric juice, focused on localized healing and GI health. PT-141 (Bremelanotide) is a melanocortin receptor agonist used for sexual dysfunction research; it shares no mechanism with TB-500. These compounds are sometimes seen together in combination protocols, but they are distinct compounds serving different purposes.

Final Thoughts on TB-500

TB-500 is one of the more mechanistically compelling peptides in the research landscape, and also one of the more honestly complicated when you look at what the evidence actually shows. The preclinical data on actin regulation, cell migration, angiogenesis, and anti-inflammation is substantive and consistent across multiple research areas. The animal model findings in wound healing, cardiac repair, and neurological recovery are meaningful. The extrapolated human data from TB4 trials provides a safety scaffold, with Phase 1 data in 84 volunteers showing no serious adverse events at doses up to 7.66 mg. That is a real evidence base. It is also an evidence base built almost entirely without completed, published human clinical trials for TB-500 specifically. The in vitro metabolite finding adds a further layer of interpretive complexity by suggesting the compound may function as a prodrug rather than a direct-acting agent.

What that means practically: TB-500 occupies a space between preliminary and moderate evidence depending on the specific application. The systemic reach, the angiogenic mechanisms, and the anti-inflammatory profile are genuinely differentiated compared to most compounds in this category. But users should be clear-eyed about what the evidence is and is not. This is real preclinical science with meaningful findings, not validated human therapeutic data. The cancelled 2015 Phase 1 trial and the unpublished 2009 TB4 wound healing trial are significant gaps that deserve acknowledgment rather than dismissal. Regulatory status is RUO in most jurisdictions, WADA-banned for all athletes, and evolving as anti-doping detection methods advance. Sourcing quality matters substantially for a compound where the N-terminal acetylation is directly tied to its mechanism.

For anyone exploring TB-500 seriously, the breadth of applications is part of the appeal and part of the complication. The right protocol depends on which application you are targeting, your specific health context, what else you are using, and what cycle structure makes sense given your goals. That kind of personalization is exactly what the MyPeptidePal protocol builder is built for. It takes the broad picture covered in this guide and translates it into a protocol that accounts for your specific situation rather than a general range. The information here is a starting point. The protocol is what you build from it.

References

1. Goldstein, A. L., Hannappel, E., & Kleinman, H. K. (2005). Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421-429.

2. Dominguez, R., & Holmes, K. C. (2011). Actin structure and function. Annual Review of Biophysics, 40, 169-186.

3. Staresinic, M., Petrovic, I., Novinscak, T., Jukic, I., Pevec, D., Suknaic, S., Kokic, N., Batelja, L., Brcic, L., Boban-Blagaic, A., Zoric, Z., Ivanovic, D., Djacovic, V., Milavic-Vukovic, V., Perovic, D., Aralica, G., Kolonic Ostojic, S., Seiwerth, S., & Sikiric, P. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research, 24(5), 1109-1117.

4. Malinda, K. M., Goldstein, A. L., & Kleinman, H. K. (1999). Thymosin beta-4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 13(2), 227-231.

Additional sources pending editorial review: the TB-500 human clinical trial landscape is notably sparse; the cancelled 2015 Phase 1 TB-500 trial and the unpublished 2009 Phase 2 TB4 dermal wound trial are referenced throughout this guide and represent significant evidence gaps. The WADA-funded metabolite research (in vitro human tissue metabolism study) is referenced in the Pharmacokinetics and Mechanistic Research sections; the full citation will be confirmed and added upon editorial review of the primary source document. The Philp et al. (2003) paper previously listed as Reference 1 has been removed: that paper covers hair growth via stem cell migration, not wound healing efficacy, and was incorrectly matched to wound healing claims throughout the article. A correctly matched wound healing citation will be added upon editorial review.